7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ha H et al. | Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. | 2003 | J. Biol. Chem. | pmid:12637570 |
Ritchlin CT et al. | Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. | 2003 | J. Clin. Invest. | pmid:12639988 |
Takahashi E et al. | High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. | 2002 | J. Med. Dent. Sci. | pmid:12641381 |
Fox SW et al. | The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. | 2003 | J. Immunol. | pmid:12646633 |
Varsani H et al. | Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). | 2003 | Rheumatology (Oxford) | pmid:12649407 |
Wise GE et al. | Regulation of osteoprotegerin gene expression in dental follicle cells. | 2003 | J. Dent. Res. | pmid:12651935 |
Schoppet M et al. | Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. | 2003 | Circulation | pmid:12654623 |
Nakano M et al. | Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. | 2003 | Oral Dis | pmid:12657033 |
Ra JS et al. | Osteoprotegerin inhibits proliferation of myeloid progenitor cells. | 2003 | J. Hematother. Stem Cell Res. | pmid:12662434 |
Szalay F et al. | High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. | 2003 | J. Hepatol. | pmid:12663228 |
Okada Y et al. | Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. | 2003 | J. Biol. Chem. | pmid:12665515 |
Johnson-Pais TL et al. | Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. | 2003 | Int. J. Cancer | pmid:12673693 |
Zaidi M et al. | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. | 2003 | J. Bone Miner. Res. | pmid:12674320 |
Terpos E et al. | Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. | 2003 | Blood | pmid:12689925 |
Zheng B et al. | MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. | 2003 | Blood | pmid:12689928 |
Moreno JL et al. | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. | 2003 | Blood | pmid:12689929 |
Dovio A et al. | Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. | 2003 | J. Endocrinol. | pmid:12697042 |
Bell NH | RANK ligand and the regulation of skeletal remodeling. | 2003 | J. Clin. Invest. | pmid:12697730 |
Eghbali-Fatourechi G et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | 2003 | J. Clin. Invest. | pmid:12697741 |
Enomoto H et al. | Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. | 2003 | J. Biol. Chem. | pmid:12697767 |
Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
Al-Qawasmi RA et al. | Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. | 2003 | J. Dent. Res. | pmid:12709501 |
Fujita D et al. | Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12711253 |
Tanaka S et al. | Signal transduction pathways regulating osteoclast differentiation and function. | 2003 | J. Bone Miner. Metab. | pmid:12720046 |
Valleala H et al. | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. | 2003 | Eur. J. Endocrinol. | pmid:12720535 |
Yonou H et al. | Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. | 2003 | Cancer Res. | pmid:12727825 |
Capparelli C et al. | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | 2003 | J. Bone Miner. Res. | pmid:12733724 |
Wong T et al. | Therapeutic implications for interferon-alpha in arthritis: a pilot study. | 2003 | J. Rheumatol. | pmid:12734885 |
Lee ZH and Kim HH | Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12745060 |
Boyle WJ et al. | Osteoclast differentiation and activation. | 2003 | Nature | pmid:12748652 |
Kanatani M et al. | Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. | 2003 | J. Cell. Physiol. | pmid:12767054 |
Cheung J et al. | Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. | 2003 | J. Endocrinol. | pmid:12773123 |
Nimmanapalli R and Bhalla K | Targets in apoptosis signaling: promise of selective anticancer therapy. | 2003 | Methods Mol. Biol. | pmid:12777745 |
Garber K | Why it hurts: researchers seek mechanisms of cancer pain. | 2003 | J. Natl. Cancer Inst. | pmid:12783923 |
Liu B et al. | Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. | 2003 | J. Oral Pathol. Med. | pmid:12787044 |
Walsh MC and Choi Y | Biology of the TRANCE axis. | 2003 Jun-Aug | Cytokine Growth Factor Rev. | pmid:12787563 |
Eaton CL and Coleman RE | Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. | 2003 | Cancer Treat. Rev. | pmid:12787713 |
Fahrleitner-Pammer A et al. | Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. | 2003 | Wien. Klin. Wochenschr. | pmid:12793029 |
Dovio A et al. | Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. | 2003 | Clin. Cancer Res. | pmid:12796409 |
Flick LM et al. | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. | 2003 | J. Orthop. Res. | pmid:12798068 |
Kido S et al. | Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. | 2003 | Bone | pmid:12810169 |
Kudlacek S et al. | Serum levels of osteoprotegerin increase with age in a healthy adult population. | 2003 | Bone | pmid:12810175 |
Khapli SM et al. | IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. | 2003 | J. Immunol. | pmid:12816992 |
Kawase Y et al. | Bone malformations in interleukin-18 transgenic mice. | 2003 | J. Bone Miner. Res. | pmid:12817749 |
Kikuchi T et al. | Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. | 2003 | J. Dent. Res. | pmid:12821717 |
D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
Knudsen ST et al. | Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. | 2003 | Eur. J. Endocrinol. | pmid:12824864 |
Ikeda T et al. | Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. | 2003 | Pathol. Int. | pmid:12828610 |
Crotti T et al. | Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. | 2003 | J. Periodont. Res. | pmid:12828654 |
Tazoe M et al. | Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. | 2003 | Arch. Oral Biol. | pmid:12828991 |
Ito R et al. | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | 2003 | Virchows Arch. | pmid:12838418 |
Terpos E et al. | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. | 2003 | Int. J. Cancer | pmid:12845688 |
Schett G et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | 2003 | Arthritis Rheum. | pmid:12847699 |
Fizazi K et al. | Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. | 2003 | Clin. Cancer Res. | pmid:12855635 |
Okuma K et al. | Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. | 2003 | J. Virol. | pmid:12857926 |
Cheng X et al. | The TNF receptor superfamily: role in immune inflammation and bone formation. | 2003 | Immunol. Res. | pmid:12857975 |
Shin MM et al. | High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. | 2003 | Exp. Mol. Med. | pmid:12858015 |
Glossop JR et al. | No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. | 2003 | J. Rheumatol. | pmid:12858434 |
Chen X et al. | Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. | 2003 | J. Nutr. Biochem. | pmid:12873716 |
Bridgham JT and Johnson AL | Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12878204 |
Riggs BL et al. | Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. | 2003 | Osteoporos Int | pmid:12879223 |
Sasaki T | Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. | 2003 | Microsc. Res. Tech. | pmid:12879416 |
Helfrich MH | Osteoclast diseases. | 2003 | Microsc. Res. Tech. | pmid:12879419 |
Younes A and Aggarwall BB | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. | 2003 | Cancer | pmid:12879461 |
Fukushima H et al. | Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. | 2003 | Eur. J. Oral Sci. | pmid:12887401 |
Min JK et al. | Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. | 2003 | J. Biol. Chem. | pmid:12893832 |
Teitelbaum SL and Ross FP | Genetic regulation of osteoclast development and function. | 2003 | Nat. Rev. Genet. | pmid:12897775 |
Si AI et al. | Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. | 2003 | J. Cell. Biochem. | pmid:12898514 |
Nitta K et al. | The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. | 2003 | Am. J. Kidney Dis. | pmid:12900812 |
Hampson G et al. | Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. | 2003 | Osteoporos Int | pmid:12904840 |
Misra M et al. | Serum osteoprotegerin in adolescent girls with anorexia nervosa. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915674 |
Lonergan M et al. | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915677 |
Kapczuk K et al. | [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. | 2003 | Ginekol. Pol. | pmid:12916277 |
Liu JZ et al. | [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. | 2003 | Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi | pmid:12916296 |
Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
Tabb MM et al. | Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. | 2003 | J. Biol. Chem. | pmid:12920130 |
Park HR et al. | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. | 2003 | J. Korean Med. Sci. | pmid:12923331 |
Paloneva J et al. | DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. | 2003 | J. Exp. Med. | pmid:12925681 |
Nawroth P et al. | [Osteoporosis and cardiovascular disease--two sides of the same coin?]. | 2003 | Med. Klin. (Munich) | pmid:12928809 |
Nakatsuka K et al. | Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. | 2003 | J. Bone Miner. Res. | pmid:12929927 |
Li JP and Ling JQ | [Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. | 2003 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:12930661 |
Schett G et al. | The role of osteoprotegerin in arthritis. | 2003 | Arthritis Res. Ther. | pmid:12932284 |
Karsdal MA et al. | Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. | 2003 | J. Biol. Chem. | pmid:12933809 |
Benevolenskaia LI | [Issues of osteoporosis in present-day medicine]. | 2003 | Vestn. Akad. Med. Nauk SSSR | pmid:12934464 |
Sugatani T et al. | Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. | 2003 | J. Cell. Biochem. | pmid:12938156 |
Yamagami H et al. | Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. | 2003 | Biochem. Pharmacol. | pmid:12948861 |
Srivastava S et al. | Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. | 2003 | J. Biol. Chem. | pmid:12952963 |
Lee HA et al. | Bumetanide, the specific inhibitor of Na+-K+-2Cl- cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. | 2003 | Exp. Physiol. | pmid:12955156 |
Yorke R et al. | Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. | 2003 | Eur. J. Cancer | pmid:12957466 |
Zhang L et al. | The role of calmodulin in the regulation of osteoclastogenesis. | 2003 | Endocrinology | pmid:12960067 |
Nakamura H et al. | Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. | 2003 | J. Med. Dent. Sci. | pmid:12968638 |
Viereck V et al. | Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12970288 |
Kaneyama K et al. | Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. | 2003 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:12973279 |
Sakurai A et al. | Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. | 2003 | Infect. Immun. | pmid:14500523 |
Kim HH et al. | RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. | 2003 | FASEB J. | pmid:14500543 |
Nakamura M et al. | Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. | 2003 | Endocrinology | pmid:14500574 |
Zhang Z et al. | Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. | 2003 | J. Immunol. | pmid:14500659 |
Naumann U et al. | Expression and functional activity of osteoprotegerin in human malignant gliomas. | 2004 | Acta Neuropathol. | pmid:14504888 |
Ueno Y et al. | In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. | 2003 | J. Cell. Biochem. | pmid:14505343 |
Kaneyama K et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. | 2003 | Int J Oral Maxillofac Surg | pmid:14505625 |